診断薬市場：製品タイプ、エンドユーザー、用途別-2025～2030年の世界予測

診断薬市場の2024年の市場規模は1,783億6,000万米ドルで、2025年にはCAGR 6.48%で1,895億3,000万米ドルに成長し、2030年には2,599億9,000万米ドルに達すると予測されています。

診断用物質は、現代の医療革新のまさに中心にあり、病気の発見と患者管理の進歩を推進しています。急速な技術進歩と臨床ニーズの進化によって定義される時代において、診断薬は著しい変化を遂げてきました。診断薬市場は、ダイナミックな研究、機器、検査、試薬の力強い開発、より迅速で正確な診断ソリューションへの需要の高まりによって特徴付けられています。

診断薬の進化は、科学的な創意工夫の証であるだけでなく、個別化医療と精密医療への世界の取り組みの反映でもあります。本レポートは、市場動向、画期的な技術、自動化された費用対効果の高いプラットフォームの新たな役割に重点を置き、診断薬の包括的な状況を掘り下げています。厳密なバリデーションプロトコル、規制基準、新たな製品タイプとエンドユーザーの需要との相互関係といった重要な要素を中心に解説しています。

広範な調査データと第一線の専門家による洞察を統合することで、本概要は市場の現状と将来の方向性をバランスよく検証しています。医療の組織やメーカーが一歩先を行くためには、製品イノベーションを推進する根本的な原動力を理解することが不可欠です。エビデンスに基づいた分析に重点を置き、明確で魅力的なイントロダクションを提供することで、以降のセクションでさらに掘り下げるための基礎となることを目的としています。

診断薬市場の変革

診断薬の状況は、市場の境界を再定義し、臨床や研究への応用に新たな道を開くような、変革的なシフトを目の当たりにしてきました。このような変化は、デジタル技術の急速な統合、分子診断学の洗練化、様々なアッセイに使用される試薬の進化に顕著に現れています。

顕著な動向のひとつは、従来の診断アプローチから高度に自動化されたシステムへと移行し、スピードと精度の両方が向上したことです。この変革的な変化は、技術主導型であるだけでなく、早期かつ正確な診断が世界的に重視されるようになったことも影響しています。次世代シークエンシングとポリメラーゼ連鎖反応（PCR）技術の進歩により、遺伝子マーカーと疾患経路のより深い調査が可能になり、個別化医療における飛躍的進歩が促進されました。

デジタル統合もまた、市場力学の再構築に重要な役割を果たしています。クラウドベースのデータ管理、画像分析における人工知能、機械学習アルゴリズムにより、検査室は膨大な量の診断データを処理・解釈する能力を手に入れました。これらの技術革新は、診断所要時間の短縮、信頼性の向上、高スループット環境におけるワークフローの最適化につながっています。装置、バイオアッセイ、試薬化学の融合により、堅牢で汎用性が高く、現代の医療と研究の要求に継続的に適応するプラットフォームが誕生しました。

市場は現在、メーカー、臨床医、研究者が連携して拡大性と信頼性の高い診断ソリューションを開発する全体的なアプローチによって特徴付けられています。この相互依存的なエコシステムは、技術革新を促進するだけでなく、患者ケアの改善を最優先事項とし、診断物質を将来の医療構想に不可欠なツールへと効果的に変化させています。

主要なセグメンテーション洞察製品、エンドユーザー、用途

診断薬市場では、需要を牽引する多様な製品、ユーザー、用途を理解する上で、セグメンテーションが極めて重要な役割を果たします。製品タイプ別内訳は、機器、キット＆アッセイ、試薬です。例えば、機器セグメントはさらに分析装置、画像診断装置、分子診断機器に分けられます。分子診断機器についてさらに掘り下げると、次世代シークエンシング技術とPCR装置が力強い伸びを示しており、これらはいずれも複雑な遺伝情報の分析方法に革命をもたらしました。一方、キットやアッセイには、ELISAキット、ラテラルフローアッセイ、PCRキット、迅速検査キットなどがあり、それぞれ特定の診断ニーズに合わせて調整され、様々な規制の枠組みの下で運用されています。同様に重要なのが試薬で、抗体試薬、抗原試薬、酵素、核酸試薬、組換えタンパク質などが含まれ、診断アッセイのバックボーンを形成します。

市場はまた、診断ラボや法医学ラボから病院クリニック、ポイントオブケア検査施設、研究・学術機関まで、エンドユーザーによっても区分されます。これらのエンドユーザーにはそれぞれ独自の要件があるため、さまざまな環境に適応できるオーダーメイドのソリューションが必要となります。例えば、診断ラボは高スループットの自動化システムから恩恵を受け、一方、POC検査施設はポータブルで迅速かつ使いやすい装置を求めています。このセグメンテーションは、様々な臨床・研究ワークフローに適応できる汎用性の高い製品プラットフォームの必要性を強調しています。

さらに、用途ベースのセグメンテーションにより、市場は臨床診断、法医学、研究に分けられます。臨床診断セグメントでは、循環器科、内分泌科、感染症科、神経科、腫瘍科などの専門セグメントにさらに細分化されます。法医学セグメントでは、血液サンプル検査、DNA分析、毒物スクリーニングなどの機能に重点が置かれています。一方、研究セグメントは、創薬、ゲノム研究、プロテオミクス研究を対象としています。このような重層的なセグメンテーション構造は、市場の複雑さを際立たせるだけでなく、急速に進化する多様な科学的・臨床的期待に応えるための診断薬の適応性を強調するものでもあります。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の罹患率の上昇により、世界中で診断薬の需要が高まっている
    • 正確で迅速な診断検査オプションに対する消費者の意識と需要の高まり
    • 高齢化が進むにつれ、より頻繁かつ多様な診断検査サービスが必要となっている
  • 抑制要因
    • サプライチェーンの混乱により診断薬の入手可能性と流通に影響が出ています
  • 機会
    • 診断薬におけるイノベーションへの投資と資金の急増
    • 物質の使用と分析の効率を高める診断の進歩
  • 課題
    • 診断薬の廃棄における環境持続可能性の懸念
• 市場セグメンテーション分析
  • 製品タイプ：高い精度と効率性を備えた診断用分析装置の需要の高まり
  • 用途：心臓関連疾患を評価するための臨床診断における診断薬の使用増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 診断薬市場：製品タイプ別

• イントロダクション
• 機器
  • アナライザ
  • 画像機器
  • 分子診断機器
    • 次世代シーケンス
    • PCRマシン
• キットとアッセイ
  • ELISAキット
  • ラテラルフローアッセイ
  • PCRキット
  • 迅速検査キット
• 試薬
  • 抗体試薬
  • 抗原試薬
  • 酵素
  • 核酸試薬
  • 組み換えタンパク質

第7章 診断薬市場：エンドユーザー別

• イントロダクション
• 診断ラボ
• 法医学ラボ
• 病院とクリニック
• ポイントオブケア検査施設
• 研究・学術機関

第8章 診断薬市場：用途別

• イントロダクション
• 臨床診断
  • 心臓病学
  • 内分泌学
  • 感染症
  • 神経学
  • 腫瘍学
• 法医学
  • 血液サンプル検査
  • DNA分析
  • 毒物学
• 研究
  • 創薬
  • ゲノミクス調査
  • プロテオミクス調査

第9章 南北アメリカの診断薬市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の診断薬市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの診断薬市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2024年
• FPNVポジショニングマトリックス、2024年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Agilent Technologies Inc.
• Asuragen, Inc. by Bio-Techne Corporation
• Becton, Dickinson and Company
• Bio-Rad Laboratories Inc.
• bioLytical Laboratories
• bioMerieux SA
• Cepheid by Danaher Corporation
• DiaSorin S.p.A.
• Enzo Biochem, Inc.
• Hitachi Ltd.
• Hoffmann-La Roche AG
• Hologic Inc.
• HyTest Ltd.
• Illumina Inc.
• Merck KGaA
• OraSure Technologies, Inc.
• Ortho Clinical Diagnostics
• Qiagen N.V.
• Quidel Corporation
• Randox Laboratories Ltd.
• Sekisui Diagnostics, LLC
• Siemens AG
• Sysmex Corporation by TOA Corporation
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. DIAGNOSTIC SUBSTANCES MARKET MULTI-CURRENCY
• FIGURE 2. DIAGNOSTIC SUBSTANCES MARKET MULTI-LANGUAGE
• FIGURE 3. DIAGNOSTIC SUBSTANCES MARKET RESEARCH PROCESS
• FIGURE 4. DIAGNOSTIC SUBSTANCES MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 15. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 17. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. DIAGNOSTIC SUBSTANCES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 23. DIAGNOSTIC SUBSTANCES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. DIAGNOSTIC SUBSTANCES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DIAGNOSTIC SUBSTANCES MARKET DYNAMICS
• TABLE 7. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY IMAGING EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RAPID TEST KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIBODY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIGEN REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENZYMES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NUCLEIC ACID REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY POINT-OF-CARE TESTING FACILITIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY BLOOD SAMPLE TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DNA ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY TOXICOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GENOMICS RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 51. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEOMICS RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 52. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 56. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 57. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 58. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 61. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 62. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 63. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 64. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 65. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 66. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 67. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 68. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 69. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 72. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 73. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 74. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 75. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 76. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 77. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 78. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 79. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 82. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 83. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 84. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 85. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 86. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 87. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 88. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 89. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 92. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 93. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 94. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 95. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 96. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 97. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 98. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 99. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 102. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 103. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 104. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 105. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 106. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 107. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 108. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 109. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 112. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 113. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 114. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 116. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 118. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 119. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 120. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 123. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 124. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 125. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 126. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 127. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 128. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 129. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 130. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 131. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 134. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 135. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 136. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 137. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 138. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 139. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 140. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 141. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 144. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 145. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 146. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 147. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 148. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 149. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 150. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 151. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 152. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 154. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 155. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 156. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 157. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 158. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 159. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 160. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 161. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 162. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 164. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 165. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 166. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 167. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 168. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 169. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 170. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 171. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 172. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 174. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 175. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 176. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 177. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 178. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 179. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 180. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 181. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 183. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 184. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 185. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 186. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 187. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 188. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 189. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 190. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 191. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 192. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 193. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 194. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 195. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 196. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 197. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 198. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 199. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 200. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 201. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 202. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 203. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 204. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 205. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 210. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 211. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 212. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 213. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 214. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 215. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 216. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 217. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 218. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 219. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 220. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 221. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 222. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 223. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 224. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 225. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 226. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 227. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 228. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 229. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 230. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 231. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 232. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 233. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 234. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 235. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 236. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 237. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 238. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 239. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 240. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 241. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 242. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 243. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 244. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 245. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 251. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 252. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 253. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 254. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 255. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 256. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 257. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 258. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 259. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 260. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 261. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 262. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 263. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 264. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 265. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 266. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 267. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 268. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 269. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 270. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 271. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 272. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 273. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 274. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 275. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 276. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 277. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 278. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 279. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 280. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 281. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 282. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 283. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 284. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 285. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 286. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 287. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 288. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 289. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 290. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 291. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 292. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 293. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 294. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 295. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 296. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 297. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 298. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 299. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 300. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 301. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 302. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 303. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 304. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 305. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 306. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 307. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 308. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 309. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 310. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 311. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 312. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 313. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 314. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 315. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 316. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 317. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 318. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 319. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 320. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 321. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 322. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 323. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 324. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 325. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
• TABLE 326. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 327. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 328. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 329. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 330. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
• TABLE 331. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
• TABLE 332. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 333. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 334. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 335. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-20

The Diagnostic Substances Market was valued at USD 178.36 billion in 2024 and is projected to grow to USD 189.53 billion in 2025, with a CAGR of 6.48%, reaching USD 259.99 billion by 2030.

Diagnostic substances are at the very heart of modern healthcare innovation, driving advances in disease detection and patient management. In an era defined by rapid technological progress and evolving clinical needs, diagnostic substances have undergone remarkable changes. The market is marked by dynamic research, robust development in instruments, tests, and reagents, and an ever-increasing demand for faster, more accurate diagnostic solutions.

The evolution of diagnostic substances is not only a testament to scientific ingenuity but also a reflection of the global commitment to personalized medicine and precision health care. This report delves into the comprehensive landscape of diagnostic substances with an emphasis on market trends, breakthrough technologies, and the emerging role of automated, cost-effective platforms. The narrative is built around key factors such as rigorous validation protocols, regulatory standards, and interconnections between emerging product types and end-user demands.

By synthesizing extensive research data with insights from leading experts, this overview presents a balanced examination of current market conditions and future directions. As healthcare organizations and manufacturers seek to stay ahead, understanding the underlying dynamics that drive product innovation is essential. With an emphasis on evidence-based analysis, the discussion aims to provide a clear, engaging introduction that serves as the foundation for further exploration in subsequent sections.

Transformative Shifts in the Diagnostic Substances Market Landscape

The landscape of diagnostic substances has witnessed transformative shifts that have redefined market boundaries and opened new avenues for clinical and research applications. These shifts are evident in the rapid integration of digital technologies, the refinement of molecular diagnostics, and the evolution of reagents used in a variety of assays.

One of the striking trends is the move from traditional diagnostic approaches to highly automated systems, which have enhanced both speed and precision. This transformative change is not only technology-driven but also influenced by a growing global emphasis on early and accurate diagnosis. Advancements in next-generation sequencing and polymerase chain reaction (PCR) technologies have allowed for a deeper investigation into genetic markers and disease pathways, facilitating breakthroughs in personalized medicine.

Digital integration has also played a key role in reshaping market dynamics. Cloud-based data management, artificial intelligence in image analysis, and machine learning algorithms have empowered laboratories with the capability to process and interpret vast amounts of diagnostic data. These innovations have led to a reduction in diagnostic turnaround time, improved reliability, and optimized workflows in high-throughput environments. The convergence of instrumentation, bioassays, and reagent chemistries has resulted in platforms that are both robust and versatile, adapting continuously to the demands of modern healthcare and research.

The market is now characterized by a holistic approach where manufacturers, clinicians, and researchers work in tandem to develop scalable and reliable diagnostic solutions. This interdependent ecosystem not only fuels innovation but also ensures that improvements in patient care remain a top priority, effectively transforming diagnostic substances into indispensable tools for future healthcare initiatives.

Key Segmentation Insights: Product, End-User, and Application

Within the diagnostic substances market, segmentation plays a pivotal role in understanding the diverse range of products, users, and applications that drive demand. A granular breakdown by product type covers instruments, kits & assays, and reagents. The instruments segment, for instance, is further dissected into analyzers, imaging equipment, and molecular diagnostic instruments. Digging deeper into molecular diagnostic instruments reveals strong growth in next-generation sequencing technologies and PCR machines, both of which have revolutionized the way complex genetic information is analyzed. Kits and assays, on the other hand, include ELISA kits, lateral flow assays, PCR kits, and rapid test kits, each tailored to meet specific diagnostic needs and operating under varied regulatory frameworks. Equally critical are the reagents, encompassing antibody reagents, antigen reagents, enzymes, nucleic acid reagents, and recombinant proteins which form the backbone of diagnostic assays.

The market is also segmented by end-users, ranging from diagnostic laboratories and forensic laboratories to hospitals & clinics, point-of-care testing facilities, and research & academic institutes. Each of these end-users has unique requirements, thus necessitating tailored solutions that can adapt to different environments. For instance, diagnostic laboratories benefit from high-throughput automated systems, while point-of-care testing facilities demand portable, swift, and easy-to-use instruments. This segmentation underscores the need for versatile product platforms capable of adapting to various clinical and research workflows.

Furthermore, application-based segmentation divides the market into clinical diagnostics, forensic, and research. Within clinical diagnostics, there is a further subdivision into specialties such as cardiology, endocrinology, infectious diseases, neurology, and oncology. In the forensic domain, the focus is on functionalities like blood sample testing, DNA analysis, and toxicology screening. The research segment, meanwhile, is targeted towards drug discovery, genomics research, and proteomics research. This layered segmentation structure not only highlights the complexity of the market but also underscores the adaptability of diagnostic substances in meeting diverse, rapidly evolving scientific and clinical expectations.

Based on Product Type, market is studied across Instruments, Kits & Assays, and Reagents. The Instruments is further studied across Analyzers, Imaging Equipment, and Molecular Diagnostic Instruments. The Molecular Diagnostic Instruments is further studied across Next-Generation Sequencing and PCR Machines. The Kits & Assays is further studied across ELISA Kits, Lateral Flow Assays, PCR Kits, and Rapid Test Kits. The Reagents is further studied across Antibody Reagents, Antigen Reagents, Enzymes, Nucleic Acid Reagents, and Recombinant Proteins.

Based on End-User, market is studied across Diagnostic Laboratories, Forensic Laboratories, Hospitals & Clinics, Point-of-Care Testing Facilities, and Research & Academic Institutes.

Based on Application, market is studied across Clinical Diagnostics, Forensic, and Research. The Clinical Diagnostics is further studied across Cardiology, Endocrinology, Infectious Diseases, Neurology, and Oncology. The Forensic is further studied across Blood Sample Testing, DNA Analysis, and Toxicology. The Research is further studied across Drug Discovery, Genomics Research, and Proteomics Research.

Key Regional Insights: Americas, Europe, Middle East & Africa, Asia-Pacific

Regional dynamics exert a profound influence on the evolution of the diagnostic substances market. The market exhibits distinct trends across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each driven by unique factors ranging from regulatory environments to levels of technological adoption.

In the Americas, particularly in North America, high investment in healthcare infrastructure and a focus on innovation have largely shaped market growth. Advanced research facilities and state-of-the-art diagnostic laboratories have set the pace for technology adoption, leading to robust demand for precision diagnostic tools. Across Europe and in parts of the Middle East and Africa, regulatory support combined with public and private partnerships has accelerated the introduction of next-generation diagnostic platforms. Stringent quality standards and an emphasis on evidence-based medicine have contributed to the steady, albeit diverse, growth in these regions.

The Asia-Pacific region is emerging as a significant growth driver with rapid urbanization, increased healthcare spending, and expanding diagnostic networks. Governments and private entities in these areas are increasingly investing in state-of-the-art diagnostic technologies to meet the rising demand in both clinical and research settings. The drive for local innovation paired with technology transfer from leading global markets has created a fertile ground for market expansion. Taken together, these regional insights indicate that while market strategies may need to be tailored to reflect local conditions, the underlying advancements remain consistently transformative across all territories.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights: Leading Innovators in Diagnostic Substances

The diagnostic substances market is characterized by the involvement of several pioneering companies whose continual innovation shapes industry trends and future directions. Leading players such as Abbott Laboratories, Agilent Technologies Inc., Asuragen, Inc. by Bio-Techne Corporation, and Becton, Dickinson and Company have been instrumental in advancing diagnostic instruments and assay technologies. Companies like Bio-Rad Laboratories Inc., bioLytical Laboratories, and bioMerieux SA further contribute by developing advanced reagents and testing kits that meet stringent quality standards.

Other notable entities include Cepheid by Danaher Corporation, DiaSorin S.p.A., Enzo Biochem, Inc., Hitachi Ltd., and Hoffmann-La Roche AG, whose research efforts have resulted in breakthrough platforms in molecular diagnostics. Emerging innovators such as Hologic Inc., HyTest Ltd., Illumina Inc., and Merck KGaA continue to push the boundaries of what is achievable in terms of predictive accuracy and diagnostic efficiency. Firms like OraSure Technologies, Inc. and Ortho Clinical Diagnostics have expanded their portfolios to include both high-throughput automated systems and rapid point-of-care solutions.

Further contributions come from Qiagen N.V., Quidel Corporation, Randox Laboratories Ltd., Sekisui Diagnostics, LLC, Siemens AG, Sysmex Corporation by TOA Corporation, and Thermo Fisher Scientific Inc. These companies not only drive technological advancements but also set industry benchmarks in quality control, regulatory compliance, and customer engagement. Together, these key industry players create an ecosystem that is responsive to emerging public health challenges and is ever-prepared to meet the demands of the evolving diagnostic landscape.

The report delves into recent significant developments in the Diagnostic Substances Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies Inc., Asuragen, Inc. by Bio-Techne Corporation, Becton, Dickinson and Company, Bio-Rad Laboratories Inc., bioLytical Laboratories, bioMerieux SA, Cepheid by Danaher Corporation, DiaSorin S.p.A., Enzo Biochem, Inc., Hitachi Ltd., Hoffmann-La Roche AG, Hologic Inc., HyTest Ltd., Illumina Inc., Merck KGaA, OraSure Technologies, Inc., Ortho Clinical Diagnostics, Qiagen N.V., Quidel Corporation, Randox Laboratories Ltd., Sekisui Diagnostics, LLC, Siemens AG, Sysmex Corporation by TOA Corporation, and Thermo Fisher Scientific Inc.. Actionable Recommendations for Industry Leaders in Diagnostic Substances

In light of the transformative shifts and nuanced segmentation within the diagnostic substances market, industry leaders are encouraged to adopt a forward-thinking approach. It is essential to invest in research and development initiatives focused on integrating digital technologies with traditional testing modalities, thereby enhancing diagnostic accuracy and speed. Companies should consider strengthening partnerships with academic institutions and specialized research centers to foster innovation through collaborative endeavors.

Optimizing supply chains and bolstering product portfolios with a balanced mix of cutting-edge instruments, robust assays, and high-quality reagents will also be critical. Furthermore, aligning product strategies with regional requirements and regulatory landscapes can unlock new market opportunities. Emphasizing sustainability, operational efficiency, and quality assurance can help ensure that organizations remain competitive in a steadily evolving market environment.

Conclusion and Future Outlook for Diagnostic Substances

The diagnostic substances market is rapidly evolving to meet the challenges of modern healthcare and research environments. Driving forces such as technological innovation, robust segmentation, and dynamic regional shifts are set to influence market trajectories for the foreseeable future. Manufacturers, clinicians, and investors must continuously adapt and leverage state-of-the-art breakthroughs to stay ahead in this competitive landscape.

In essence, the market's ability to integrate diverse diagnostic tools and methodologies into cohesive platforms reflects a broader trend towards personalized medicine and precision diagnostics. As the industry moves forward, the focus on harmonizing product development with evolving clinical needs will undoubtedly catalyze further breakthroughs. Stakeholders who invest in cutting-edge research and strategic collaborations are best positioned to harness the immense potential of these innovations, ensuring long-term success and improved patient outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of chronic diseases spurs greater demand for diagnostic substances worldwide
    • 5.1.1.2. Increasing consumer awareness and demand for accurate and rapid diagnostic testing options
    • 5.1.1.3. Growing geriatric population necessitating more frequent and diverse diagnostic testing services
  • 5.1.2. Restraints
    • 5.1.2.1. Supply chain disruptions impacting the availability and distribution of diagnostic substances
  • 5.1.3. Opportunities
    • 5.1.3.1. Surging investments & funding for innovations in diagnostic substances
    • 5.1.3.2. Advancements in diagnostics to enhance efficiency in substance usage and analysis
  • 5.1.4. Challenges
    • 5.1.4.1. Environmental sustainability concerns in the disposal of diagnostic substances
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product Type: Rising demand of analyzers for diagnosis with heightened accuracy and efficiency
  • 5.2.2. Application: Growing usage of diagnostic substances in clinical diagnostics for assessing heart-related conditions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Diagnostic Substances Market, by Product Type

• 6.1. Introduction
• 6.2. Instruments
  • 6.2.1. Analyzers
  • 6.2.2. Imaging Equipment
  • 6.2.3. Molecular Diagnostic Instruments
    • 6.2.3.1. Next-Generation Sequencing
    • 6.2.3.2. PCR Machines
• 6.3. Kits & Assays
  • 6.3.1. ELISA Kits
  • 6.3.2. Lateral Flow Assays
  • 6.3.3. PCR Kits
  • 6.3.4. Rapid Test Kits
• 6.4. Reagents
  • 6.4.1. Antibody Reagents
  • 6.4.2. Antigen Reagents
  • 6.4.3. Enzymes
  • 6.4.4. Nucleic Acid Reagents
  • 6.4.5. Recombinant Proteins

7. Diagnostic Substances Market, by End-User

• 7.1. Introduction
• 7.2. Diagnostic Laboratories
• 7.3. Forensic Laboratories
• 7.4. Hospitals & Clinics
• 7.5. Point-of-Care Testing Facilities
• 7.6. Research & Academic Institutes

8. Diagnostic Substances Market, by Application

• 8.1. Introduction
• 8.2. Clinical Diagnostics
  • 8.2.1. Cardiology
  • 8.2.2. Endocrinology
  • 8.2.3. Infectious Diseases
  • 8.2.4. Neurology
  • 8.2.5. Oncology
• 8.3. Forensic
  • 8.3.1. Blood Sample Testing
  • 8.3.2. DNA Analysis
  • 8.3.3. Toxicology
• 8.4. Research
  • 8.4.1. Drug Discovery
  • 8.4.2. Genomics Research
  • 8.4.3. Proteomics Research

9. Americas Diagnostic Substances Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Diagnostic Substances Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Diagnostic Substances Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. FPNV Positioning Matrix, 2024
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Roche launched cobas Mass Spec solution to transform mass spectrometry diagnostics
  • 12.3.2. VION Biosciences acquired Ansh Labs enhances global diagnostic capabilities
  • 12.3.3. Bio-Rad launches first ultrasensitive multiplexed digital PCR assay
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Agilent Technologies Inc.
• 3. Asuragen, Inc. by Bio-Techne Corporation
• 4. Becton, Dickinson and Company
• 5. Bio-Rad Laboratories Inc.
• 6. bioLytical Laboratories
• 7. bioMerieux SA
• 8. Cepheid by Danaher Corporation
• 9. DiaSorin S.p.A.
• 10. Enzo Biochem, Inc.
• 11. Hitachi Ltd.
• 12. Hoffmann-La Roche AG
• 13. Hologic Inc.
• 14. HyTest Ltd.
• 15. Illumina Inc.
• 16. Merck KGaA
• 17. OraSure Technologies, Inc.
• 18. Ortho Clinical Diagnostics
• 19. Qiagen N.V.
• 20. Quidel Corporation
• 21. Randox Laboratories Ltd.
• 22. Sekisui Diagnostics, LLC
• 23. Siemens AG
• 24. Sysmex Corporation by TOA Corporation
• 25. Thermo Fisher Scientific Inc.